Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland - Fig 1

<p>Proportion of patients free of relapses (a), free of EDSS worsening (b), free of NT2 lesions (c) and with not evidence of disease activity (NEDA) (d) during 36 months of follow up in RRMS (green) and PMS patients (red) under treatment with RTX.